Skip to main content
Premium Trial:

Request an Annual Quote

Gene Myers, Graham Cameron, Duncan Campbell, Michael Liebman, Jens Finnern, Ralph Humberg, Manfred Voglmaier, Jrgen Klenk

Premium

Gene Myers has joined the scientific advisory board of CuraGen’s genomics technology subsidiary 454 Life Sciences. As VP of informatics at Celera Genomics, Myers led the assembly and analysis of the company’s human genome sequencing project. He is currently a professor of computer science at the University of California, Berkeley.

 

Confirmant has named several new members to is scientific advisory board: Graham Cameron, associate director of the EBI; Duncan Campbell, director of the MRC HGMP Resource Center at the Wellcome Trust Genome Campus; and Michael Liebman, director of computational biology and biomedical informatics at the Abramson Cancer Center of the University of Pennsylvania.

 

Munich, Germany-based bioinformatics firm Definiens has named Jens Finnern as director of business development, Ralph Humberg as director of channel sales, and Manfred Voglmaier as director of sales. The company also promoted J rgen Klenk from director of R&D to VP and CTO. Prior to joining Definiens, Finnern was the executive managing director of the German Cancer Institute, Humberg worked as director of marketing for ADVA Optical Networking, and Voglmaier was managing director of NuGenesis Technologies.

 

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.